AXON — Axon Enterprise, Inc.

The tape, not the fundamentals, is driving sentiment as of 2026-09-13: AXON is down 7.1% in a week and 20.1% in a month to $479.34, RSI(14) sits at 35.93, and price is below its 20-, 50- and 200-day SMAs (-15.6%, -14.9%, -5.0% respectively). Two things amplified the de-rating: the 10-year Treasury pushing near 4.8%, which mechanically compresses the multiple on a long-duration grower, and conspicuous insider selling in late August/early September 2026 (President Joshua Isner ~$9.6M, Chief Product Officer Jeffrey Kunins ~$6M). This is happening against an objectively strong backdrop - Q2 2026 revenue of $904M (+35% YoY), raised FY26 guidance, and an analyst consensus of 18 Buy / 4 Hold with a $652.14 mean target - so the bearishness is valuation- and rate-driven, not thesis-driven.

Revenue has compounded relentlessly for three years with no down quarter: $413M (Q3 2023) -> $430M (Q4 2023) -> $460M (Q1 2024) -> $503M (Q2 2024) -> $544M (Q3 2024) -> $575M (Q4 2024) -> $604M (Q1 2025) -> $669M (Q2 2025) -> $711M (Q3 2025) -> $797M (Q4 2025) -> $807M (Q1 2026) -> $904M (Q2 2026). YoY growth is stable-to-accelerating, not decelerating: +32.8% (2025Q2), +30.6% (2025Q3), +38.5% (2025Q4), +33.8% (2026Q1), +35.3% (2026Q2) - the 2026Q1 figure is a genuine acceleration on the two-year stack, not a seasonal blip. Gross margin is remarkably steady at 57.9%-60.8% across all twelve quarters, so the top-line growth is not being bought with price. The more interesting inflection is in operating margin: it was negative or near-zero through 2025 (-1.3% Q1, +0.2% Q2, -0.3% Q3, +1.3% Q4) then jumped to 3.6% in 2026Q1 and 5.2% in 2026Q2 - the first real evidence of operating leverage, and it is being earned while R&D spending has ramped to $208.7M in 2026Q2 (23% of revenue) versus $151.0M (25% of revenue) a year earlier. Critically, GAAP net income is nearly useless as a trend signal here: 2026Q1 net income was $169.3M against operating income of only $29.2M, and 2024Q4 net income was $135.2M against an operating loss of -$15.7M, both clearly driven by non-operating/mark-to-market items. Free cash flow is lumpy and seasonal (strong Q4s: $225M in 2024, $155M in 2025; weak H1s) but the trailing-twelve-month figure has genuinely deteriorated, from ~$330M for the four quarters ending 2025Q2 to ~$133M for the four quarters ending 2026Q2, driven by negative operating cash flow in 2026Q1 (-$31.5M) and a near-zero $20.1M in 2026Q2 while capex runs $21-23M per quarter. That FCF compression - likely working-capital and deferred-revenue related, but unproven - is the single trend worth tracking most closely next quarter.

Expensive on earnings, roughly in line with its own history on sales. As of 2026-09-13 at $479.34: trailing P/E of 193.1x versus a 5-year average of 165.9x (above its own history), forward P/E of ~62x on the $7.713 next-FY EPS estimate, P/S of 12.0x versus a 5-year average of 14.46x (below its own history), EV/EBITDA of 92.7x, P/B of 10.5x, and a price-to-cash of 57.1x. The headline PEG of -4.62 is meaningless because trailing GAAP EPS is distorted by non-operating items; on non-GAAP numbers the PEG is closer to 1.7-2.0. The honest verdict: this is a premium franchise trading at a premium price. The 12x sales multiple is not aberrational relative to its own 14.5x five-year average, which is precisely why the deterministic model calls valuation 'Neutral vs. its own history' - but 62x forward earnings and 93x EV/EBITDA leave essentially no room for a growth or margin miss, and the 20% one-month drawdown is the market demonstrating exactly how violently that math resets when rates move.

The stock is pricing in growth that has already shown up - and then some. Trailing GAAP EPS of $2.483 is close to worthless as a valuation anchor (it is squeezed by ~$800M+/year of R&D and heavy stock-based comp, and inflated in some quarters by non-operating gains). The numbers that actually matter are the $7.713 FY2026 non-GAAP EPS estimate and whether the ~35% revenue growth rate persists into FY2027. At $479.34 you are paying ~62x FY2026E and ~46x a reasonable FY2027E of roughly $10.40 - a multiple that only works if growth stays above ~28% and GAAP operating margin keeps climbing from 5.2% toward high single digits. If Q3/Q4 deliver another 30%+ revenue print with ARR holding above the $1.5B run-rate, the current price will look like a reasonable entry into a durable compounder. If growth slips to the low-20s or the operating-margin inflection stalls, there is a second leg down, because at 12x sales the stock has no valuation floor to catch it.

Clearly broken in the short term, only lightly dented in the long term, as of 2026-09-13. RSI(14) of 35.93 is weak but not yet a textbook oversold <30 reading; price is 15.6% below the 20-day SMA (~$568), 14.9% below the 50-day SMA (~$563), and 5.0% below the 200-day SMA (~$505). The stock is -7.1% over one week and -20.1% over one month, yet still +8.5% over three months and -3.4% over six months - so this is a sharp correction within a still-intact longer-term uptrend, not a structural breakdown. For anyone thinking about entry timing: the last month has punished knife-catching, and the cleanest signal would be a reclaim of the 20-day SMA or an RSI move back above 45, rather than simply buying the 20% discount. The 52-week range of $339.01-$792.16 is a useful reality check - $479.34 sits in the lower-middle of that band, but downside to the 52-week low is still ~29%.

• Interest rates / discount rates: with the 10-year Treasury near 4.8%, long-duration growth equities face mechanical multiple compression. This is the single largest driver of the recent 20% drawdown, and AXON's 1.40 beta amplifies the move in both directions.
• Municipal and federal law enforcement budget cycles: spending is currently resilient, supported by counter-drone (Dedrone) and drone-as-first-responder demand, but a recession-driven squeeze on municipal budgets would directly hit Axon's core customer base.
• Regulation and political risk around surveillance and AI in policing: generative tools like Draft One and body-camera/evidence systems are exposed to shifting public policy, litigation, and procurement pushback, which can slow adoption even without a revenue hit.
• Public-safety technology competition: Motorola Solutions and emerging AI-native entrants compete for the same budget lines, and while Axon Evidence creates powerful ecosystem lock-in, hardware (TASER, cameras, drones) remains exposed to commoditization and price pressure.
• Hardware supply chain and tariffs: the Connected Devices segment depends on imported components and manufacturing capacity, so tariff shifts or component cost inflation flow straight into a gross margin that has only ever held in a 58-61% band.

• Q3 2026 earnings (expected early November 2026): the key checks are whether software ARR (crossed $1.5B in 2026) holds a 30%+ growth rate, gross margin stays near 60%, and management raises full-year revenue guidance above the current ~$3.7B implied range.
• AI product scaling: deployment milestones for Draft One (police report writing) and other AI productivity tools, which carry software-level margins and are the clearest path to the operating-margin expansion the stock needs.
• Continued operating-margin inflection: GAAP operating margin moved from -0.3% (2025Q3) to +5.2% (2026Q2); a third consecutive quarter of expansion would materially strengthen the bull case and could re-rate the multiple.
• Federal and international contract awards, particularly counter-drone/Dedrone and drone-as-first-responder programs, which expand the addressable market beyond domestic policing.
• Rate relief: any meaningful decline in Treasury yields would decompress the discount rate applied to AXON's long-duration cash flows and disproportionately benefit a 62x forward-earnings stock.

• Extreme valuation with no cushion: 193x trailing GAAP EPS, ~62x forward non-GAAP EPS, 92.7x EV/EBITDA and 12x sales. The last month's 20.1% decline is proof that a modest change in the rate or growth outlook translates into a violent price move.
• Insider selling: President Joshua Isner (~$9.6M) and Chief Product Officer Jeffrey Kunins (~$6M) sold in late August/early September 2026, a negative signal when paired with a falling share price.
• Free cash flow deterioration: trailing-twelve-month FCF fell to roughly $133M (four quarters ending 2026Q2) from ~$330M a year earlier, with operating cash flow of -$31.5M in 2026Q1 and just $20.1M in 2026Q2 against $21-23M of quarterly capex. A GAAP-strong, cash-weak pattern is the classic accrual-quality warning.
• Balance sheet leverage stepped up sharply: long-term debt tripled from $680.3M (2024Q4) to $1.73B (2026Q2), a meaningful increase in interest cost during a period of elevated rates.
• Growth durability risk: the premium multiple depends on sustained ~30%+ revenue growth; a deceleration to the low-20s from a TASER 10 or Dedrone product-cycle slip would compress the multiple hard.
• Regulatory/reputational exposure from AI-assisted policing and evidence management, plus municipal budget tightening risk if the economy slows.

AXON is genuinely one of the better fundamental compounders in the market - 35% revenue growth, a 60% gross margin that has not budged in three years, a government-funded ecosystem moat around Axon Evidence, and a fresh operating-margin inflection (5.2% in 2026Q2 versus roughly zero a year earlier) - but at 62x forward non-GAAP EPS on a stock whose TTM free cash flow has fallen to ~$133M, this is a great business at a full price. My honest read is that this is a reasonable accumulation zone for a long-duration investor rather than the bargain the 20% drawdown superficially suggests, and I would want to see price reclaim its 20-day moving average (~$568) or RSI move back above 45 before treating the pullback as finished. This is analysis, not personalized advice.

I applied a justified ~50x forward non-GAAP P/E - derived from a PEG of ~1.75 on Axon's ~28-30% sustainable growth rate - to my own FY2027E non-GAAP EPS of about $10.40 (FY2027E revenue of ~$4.7B, +27% off the ~$3.72B FY2026 guide, at an ~18% non-GAAP net margin on ~81M diluted shares). Cross-checked: $520 implies ~11.3x FY2026E sales versus the stock's own 5-year average P/S of 14.46x and ~46x FY2027E earnings, which is a defensible premium for a 30%-growth, 60%-gross-margin franchise without endorsing the sell-side's $652-690 targets, which require assuming both sustained 30%+ growth and multiple expansion at the same time.